Brocq-lyell syndrome induced by phenytoin. Clinical case
International Journal of Development Research
Brocq-lyell syndrome induced by phenytoin. Clinical case
Received 03rd May, 2019; Received in revised form 06th June, 2019; Accepted 14th July, 2019; Published online 28th August, 2019
Copyright © 2019, Erick Magdiel Ramírez Rayón et al.. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Stevens Johnson Syndrome (SJS) has been defined as a vesiculobullous multiforme erythema of the skin and other organs. It is considered to be the initial stage of a skin reaction which most severe form of presentation is Toxic Epidermal Necrolysis (TEN), characterized by intense pain and loss of the epithelial surface (greater than 30% of the body surface), compromising the vital functions of the organism, that produced electrolyte imbalance, kidney and ocular involvement, with high catabolism and potential risk of sepsis. Etiologically it is related to the use of drugs in 80% of cases. The treatment includes several immunomodulators, among which are systemic corticosteroids, cyclosporine, intravenous immunoglobulin, cyclophosphamide, plasmapheresis and inhibitors of tumor necrosis factor alpha. We reported a case of a 27-year-old woman with anticonvulsant treatment with phenytoin, who developed a NET which she survived due to the multidisciplinary approach in the hospital unit.
